GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
331 articles on this topic
-

Semaglutide Implant: What Four Weeks Can Tell Us
A small first human study compared an experimental implant with low-dose Wegovy. The results concern early drug delivery and side effects, not a year of weight loss.
-

SUSTAIN 10 Trial Results: Blood Sugar and Weight
In a trial of 577 adults with type 2 diabetes, semaglutide had larger average blood-sugar and weight reductions than liraglutide. More stopped it because of side effects.
-

Zepbound vs Wegovy Heart Study: No Clear Winner
A new look at insurance records did not establish better heart protection with either medicine. Its main result was uncertain and changed with the analysis.
-

CDC GLP-1 Survey: 44% Changed Their Prescribed Use
About 1 in 10 adults reported GLP-1 use. The new CDC report found frequent changes to prescribed use, especially among people taking compounded medicine.
-

FEHB GLP-1 Coverage 2027: Yes, With a Therapy Rule
Federal plans must still cover at least one GLP-1 for weight management. The new therapy requirement makes the 2027 brochure worth checking before December 14.
-

Semaglutide vs Resmetirom: No Clear Liver Winner
A six-month records study found different changes in weight, liver blood tests and cholesterol. It cannot tell us which medicine protects the liver better.
-

GLP-1 Prior Authorization Renewal January: 3 Dates
January is not a universal authorization deadline. Your approval letter, continuation records, and next plan's rules decide which paperwork comes next.
-

Tamiflu and Ozempic: Can They Be Taken Together?
Their labels name no direct interaction, but nausea, fluid loss and kidney function still matter. A clinician sets the flu-treatment and semaglutide plan.
-

Medicaid GLP-1 Coverage Study: Paid Fills Fell 84%
Four states ended weight-loss coverage. Medicaid-paid prescriptions fell sharply, but the data cannot show who stopped treatment or what happened next.
-

Novocare Wegovy: What's Live and What's Coming
Novo's expanded support program adds a free membership and app around Wegovy. Insured home delivery and rewards points are announced additions, with separate eligibility and launch details.
-

What to Do After Stopping GLP-1: Five Paths
People who stopped without another treatment remained about 4% below their original weight in a new study. Other paths had larger averages, but no result chooses a treatment for you.
-

CagriSema Lower Dose: 19% Loss With Side Effects
REDEFINE 9 found about 19% average weight loss at lower CagriSema doses when counting everyone assigned treatment. Gut symptoms remained common, and close results don't prove equal doses.
-

CVS GLP-1 Study: Savings Fell Short of Drug Costs
CVS found lower medical spending among GLP-1 users, but added drug costs were higher. The plan's budget and a patient's health value are different questions.
-

GLP-1 Insurance Denial Study: One in Three Denied
About one in three initial requests was denied. Half of denials involved plan exclusions or coverage limits, despite patients meeting clinical criteria.
-

Semaglutide Binge Eating Study Finds Mixed Results
A Penn trial found improvements in eating control and body-image worries during obesity treatment. The groups did not differ significantly in reductions in binge episodes.
-

STEP 2 Trial Results: Weight and Blood Sugar
For adults with type 2 diabetes, STEP 2 compared two semaglutide doses with placebo. Here’s what its weight and blood-sugar results mean.
-

Zepbound for Teens: New Results, Adult Label
New tirzepatide results add evidence for teenagers with obesity. The current U.S. Zepbound label still covers adults.
-

FSA Prescription Receipt Deadline: Year-End Dates
The FSA prescription receipt deadline may fall after the expense deadline. Your employer’s plan sets the filing date, grace period and carryover rules.
-

Semaglutide Before Fasting Blood Test: The Plan
A routine fasting blood draw has no automatic semaglutide stop rule. The test order and the full medicine list shape the preparation plan.
-

Semaglutide and MRI Contrast: Is a Pause Needed?
MRI contrast alone does not automatically require a semaglutide pause. Kidney health, the scan’s preparation rules and any sedation shape the plan.
Page 1 of 17 · 331 articles